Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1

Interventions

binimetinib 1belinostat 1Vincristine 1Topotecan 1Lasers 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eye Neoplasms × belinostat × 1 year × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡